Familial Dysautonomia Model Reveals Ikbkap Deletion Causes Apoptosis Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Reciprocal Effort Towards Better Approaches for Drug Discovery
Acta Pharmacologica Sinica (2013) 34: 765–776 npg © 2013 CPS and SIMM All rights reserved 1671-4083/13 $32.00 www.nature.com/aps Review iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery Ru ZHANG1, Li-hong ZHANG2, Xin XIE1, 2, * 1Laboratory of Receptor-based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China; 2CAS Key Laboratory of Receptor Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China The revolutionary induced pluripotent stem cell (iPSC) technology provides a new path for cell replacement therapies and drug screen- ing. Patient-specific iPSCs and subsequent differentiated cells manifesting disease phenotypes will finally position human disease pathology at the core of drug discovery. Cells used to test the toxic effects of drugs can also be generated from normal iPSCs and pro- vide a much more accurate and cost-effective system than many animal models. Here, we highlight the recent progress in iPSC-based cell therapy, disease modeling and drug evaluations. In addition, we discuss the use of small molecule drugs to improve the genera- tion of iPSCs and understand the reprogramming mechanism. It is foreseeable that the interplay between iPSC technology and small molecule compounds will push forward the applications of iPSC-based therapy and screening systems in the real world and eventually revolutionize the methods used to treat diseases. Keywords: induced pluripotent stem cells (iPSCs); disease modeling; drug screening; toxicity evaluation; cell replacement therapy; small molecules; drug development Acta Pharmacologica Sinica (2013) 34: 765–776; doi: 10.1038/aps.2013.21; published online 22 Apr 2013 Introduction his/her own iPSCs[1–3]. -
Pediatric Autonomic Disorders
STATE-OF-THE-ART REVIEW ARTICLE Editor’s Note The Journal is interested in receiving for review short articles (1000 words) summarizing recent advances which have been made in the past 2 or 3 years in specialized areas of research and patient care. Pediatric Autonomic Disorders Felicia B. Axelrod, MDa, Gisela G. Chelimsky, MDb, Debra E. Weese-Mayer, MDc aDepartment of Pediatrics and Neurology, New York University School of Medicine, New York, New York; bDepartment of Pediatrics, Case Western Reserve School of Medicine, Cleveland, Ohio; cDepartment of Pediatrics, Rush University School of Medicine, Chicago, Illinois The authors have indicated they have no financial relationships relevant to this article to disclose. ABSTRACT The scope of pediatric autonomic disorders is not well recognized. The goal of this review is to increase awareness of the expanding spectrum of pediatric autonomic disorders by providing an overview of the autonomic nervous system, including www.pediatrics.org/cgi/doi/10.1542/ peds.2005-3032 the roles of its various components and its pervasive influence, as well as its doi:10.1542/peds.2005-3032 intimate relationship with sensory function. To illustrate further the breadth and Key Words complexities of autonomic dysfunction, some pediatric disorders are described, autonomic nervous system, cardiovascular, concentrating on those that present at birth or appear in early childhood. sympathetic nervous system, parasympathetic nervous system, viscerosensory Abbreviations FD—familial dysautonomia ANS—autonomic nervous system CAN—central autonomic network PHOX2B—paired-like homeobox 2B NGF—nerve growth factor CFS—chronic fatigue syndrome HSAN—hereditary sensory and autonomic neuropathy CIPA—congenital insensitivity to pain with anhidrosis CCHS—congenital central hypoventilation syndrome CVS—cyclic vomiting syndrome POTS—postural orthostatic tachycardia Accepted for publication Feb 13, 2006 Address correspondence to Felicia B. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
UC San Francisco Electronic Theses and Dissertations
UCSF UC San Francisco Electronic Theses and Dissertations Title Chemical genetic approaches to study protein kinase signaling pathways Permalink https://escholarship.org/uc/item/0sn1j4nk Author Hertz, Nicholas T. Publication Date 2013 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Copyright 2013 by Nicholas T. Hertz ii Acknowledgements I would like to thank Kevan for his support, insight, encouragement and enthusiasm for science. I would also like to thank Al for all of his support and encouragement. My parents were instrumental in me getting to this point and I want to thank them for their continued support and my wife Janel for everything. Part of this thesis is a reproduction of material previously published, and contains contributions from collaborators listed therein. Chapter 1 is reproduced in part with permission from: Hertz, N.T., Wang, B.T., Allen, J.J., Zhang, C., Dar, A.C., Burlingame, A.L., and Shokat, K.M., Chemical genetic approach for kinase-substrate mapping by covalent capture of thiophosphopeptides and analysis by mass spectrometry, Current Protocols in Chemical Biology. 2010, February; 2:(15-36). Chapter 2 is reproduced in part with permission from: Ultanir, S.K.*, Hertz, N.T.*, Li, G., Ge1, W.P., Burlingame, A.L., Pleasure, S.J., Shokat, K.M., Jan, L.Y., and Jan, Y., Chemical genetic identification of NDR1/2 kinase substrates AAK1 and Rabin8 uncovers their roles in controlling dendrite arborization and synapse maturation. Neuron. 2012, March 22; 73:1127-42. Chapter 3 is reproduced in part with permission from: Hengeveld, R.C.C.*, Hertz, N.T.*, Vromans, M.J.M., Zhang, C., Burlingame, A.L., Shokat, K.M., Lens, S.M.A., Development of a chemical genetic approach for human Aurora B kinase identifies novel substrates of the chromosomal passenger complex. -
What Is the Autonomic Nervous System?
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.suppl_3.iii31 on 21 August 2003. Downloaded from AUTONOMIC DISEASES: CLINICAL FEATURES AND LABORATORY EVALUATION *iii31 Christopher J Mathias J Neurol Neurosurg Psychiatry 2003;74(Suppl III):iii31–iii41 he autonomic nervous system has a craniosacral parasympathetic and a thoracolumbar sym- pathetic pathway (fig 1) and supplies every organ in the body. It influences localised organ Tfunction and also integrated processes that control vital functions such as arterial blood pres- sure and body temperature. There are specific neurotransmitters in each system that influence ganglionic and post-ganglionic function (fig 2). The symptoms and signs of autonomic disease cover a wide spectrum (table 1) that vary depending upon the aetiology (tables 2 and 3). In some they are localised (table 4). Autonomic dis- ease can result in underactivity or overactivity. Sympathetic adrenergic failure causes orthostatic (postural) hypotension and in the male ejaculatory failure, while sympathetic cholinergic failure results in anhidrosis; parasympathetic failure causes dilated pupils, a fixed heart rate, a sluggish urinary bladder, an atonic large bowel and, in the male, erectile failure. With autonomic hyperac- tivity, the reverse occurs. In some disorders, particularly in neurally mediated syncope, there may be a combination of effects, with bradycardia caused by parasympathetic activity and hypotension resulting from withdrawal of sympathetic activity. The history is of particular importance in the consideration and recognition of autonomic disease, and in separating dysfunction that may result from non-autonomic disorders. CLINICAL FEATURES c copyright. General aspects Autonomic disease may present at any age group; at birth in familial dysautonomia (Riley-Day syndrome), in teenage years in vasovagal syncope, and between the ages of 30–50 years in familial amyloid polyneuropathy (FAP). -
1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A -
The Latest in Research in Familial Dysautonomia
2018 – 2019 YEAR IN REVIEW THE LATEST IN RESEARCH IN FAMILIAL DYSAUTONOMIA _______ A MESSAGE FROM OUR DIRECTOR______ ver the last 12 months, the Center’s research efforts have continued us on the path of finding better treatments. There has never been a more O exciting time when it comes to developing new therapies for neurological diseases. In other rare diseases, it has been possible to edit genes, fix protein production, and even cure illnesses with a single infusion. These new treatments have been accomplished thanks to basic scientists and clinicians working together. Over the last 11-years, I have watched the Center grow into a powerhouse of clinical care as well as research built on training, learning, and collaboration. The team at the Center has built a research framework on an international scale, which means no patient will be left behind when it comes to developing treatments. We now follow patients in the United States, Israel, Canada, England, Belgium, Germany, Argentina, Brazil, Australia and Mexico. The natural history study where we collect all clinical and laboratory data is helping us design the trials to get new treatments in to the clinic as required by the US Food and Drug Administration (FDA). In December 2018, I visited Israel to attend the family caregiver conference and made certain that all Israeli patients participate in the natural history study, a critical step to enroll the necessary number of patients. Because FD is a rare disease, we need patients from all corners of the globe to participate. Geographical constraints should not limit be a limit to the progress we can make for FD. -
Early Diagnosis of Familial Dysautonomia Case Report with Special Reference to Primary Patho-Physiological Findings
Arch Dis Child: first published as 10.1136/adc.43.230.455 on 1 August 1968. Downloaded from Arch. Dis. Childh., 1968, 43, 455. Early Diagnosis of Familial Dysautonomia Case Report with Special Reference to Primary Patho-physiological Findings JANET GOODALL*, ELLIOT SHINEBOURNE, and BRIAN D. LAKE From the Sheffield Children's Hospital; the Department of Cardiology, St. Bartholomew's Hospital, London; and the Department of Morbid Anatomy, The Hospital for Sick Children, Great Ormond Street, London The symptoms and signs of familial dysautonomia to the care of Dr. Dennis Cottom at The Hospital for were first gathered into a clinical entity by Riley Sick Children, Great Ormond Street. et al. in 1949. A review by Riley and Moore published in 1966 reveals how much has since Clinical features. An ill baby with dilated pupils, been elucidated about the condition and how much she lay in opisthotonus which increased with crying. still remains obscure. Most of the cases reported There was marked abdominal distension with visible come from the USA, though the majority of the peristalsis, though frequent amounts of stool were being patients are of Jewish extraction and have ancestors passed. Tone was poor and the tendon reflexes were not elicited. The skin was grey and cool but became who come from Eastern Europe (P. Brunt, 1967, copyright. mottled when she cried. She was afebrile. Subse- personal communication; publication pending). It, quently, it was noted that though she could suck and therefore, seems likely that the paucity of reports swallow, these two actions were not synchronized, and in the British literature (McKendrick, 1958; as a result food was repeatedly aspirated. -
Supplementary Table 2
Supplementary Table 2. Differentially Expressed Genes following Sham treatment relative to Untreated Controls Fold Change Accession Name Symbol 3 h 12 h NM_013121 CD28 antigen Cd28 12.82 BG665360 FMS-like tyrosine kinase 1 Flt1 9.63 NM_012701 Adrenergic receptor, beta 1 Adrb1 8.24 0.46 U20796 Nuclear receptor subfamily 1, group D, member 2 Nr1d2 7.22 NM_017116 Calpain 2 Capn2 6.41 BE097282 Guanine nucleotide binding protein, alpha 12 Gna12 6.21 NM_053328 Basic helix-loop-helix domain containing, class B2 Bhlhb2 5.79 NM_053831 Guanylate cyclase 2f Gucy2f 5.71 AW251703 Tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 5.57 NM_021691 Twist homolog 2 (Drosophila) Twist2 5.42 NM_133550 Fc receptor, IgE, low affinity II, alpha polypeptide Fcer2a 4.93 NM_031120 Signal sequence receptor, gamma Ssr3 4.84 NM_053544 Secreted frizzled-related protein 4 Sfrp4 4.73 NM_053910 Pleckstrin homology, Sec7 and coiled/coil domains 1 Pscd1 4.69 BE113233 Suppressor of cytokine signaling 2 Socs2 4.68 NM_053949 Potassium voltage-gated channel, subfamily H (eag- Kcnh2 4.60 related), member 2 NM_017305 Glutamate cysteine ligase, modifier subunit Gclm 4.59 NM_017309 Protein phospatase 3, regulatory subunit B, alpha Ppp3r1 4.54 isoform,type 1 NM_012765 5-hydroxytryptamine (serotonin) receptor 2C Htr2c 4.46 NM_017218 V-erb-b2 erythroblastic leukemia viral oncogene homolog Erbb3 4.42 3 (avian) AW918369 Zinc finger protein 191 Zfp191 4.38 NM_031034 Guanine nucleotide binding protein, alpha 12 Gna12 4.38 NM_017020 Interleukin 6 receptor Il6r 4.37 AJ002942 -
Rectifier of Aberrant Mrna Splicing Recovers Trna Modification in Familial Dysautonomia
Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia Mayumi Yoshidaa, Naoyuki Kataokab,1, Kenjyo Miyauchic, Kenji Ohea,d, Kei Iidaa,e, Suguru Yoshidaf, Takayuki Nojimag, Yukiko Okunoa,e, Hiroshi Onogia,h, Tomomi Usuii, Akihide Takeuchia, Takamitsu Hosoyaf, Tsutomu Suzukic, and Masatoshi Hagiwaraa,1 aDepartment of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan; bLaboratory for Malignancy Control Research, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan; cDepartment of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo 113-8510, Japan; dKyoto University Graduate School of Medicine, Kyoto 606-8501, Japan; eMedical Research Support Center, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan; fLaboratory of Chemical Bioscience, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo 101-0062, Japan; gSir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom; hKinoPharma, Inc., Tokyo 154-0024, Japan; and iLaboratory of Gene Expression, School of Biomedical Science, Tokyo Medical and Dental University, Tokyo 113-8510, Japan Edited by Gideon Dreyfuss, University of Pennsylvania, Philadelphia, PA, and approved December 30, 2014 (received for review August 12, 2014) Familial dysautonomia (FD), a hereditary sensory and autonomic pneumonia, vomiting/dysautonomic crisis, gastrointestinal dys- neuropathy, is caused by missplicing of exon 20, resulting from an function, decreased sensitivity to pain and temperature, and intronic mutation in the inhibitor of kappa light polypeptide gene defective lacrimation. FD is a very common disorder in the enhancer in B cells, kinase complex-associated protein (IKBKAP) Ashkenazi Jewish population, with a carrier frequency of 1 in 27. -
Whole Transcriptomic Expression Differences in EBV Immortalized Versus Primary B-Cells
W&M ScholarWorks Undergraduate Honors Theses Theses, Dissertations, & Master Projects 12-2010 Whole Transcriptomic Expression Differences in EBV Immortalized versus Primary B-Cells Dolores Huberts College of William and Mary Follow this and additional works at: https://scholarworks.wm.edu/honorstheses Part of the Biology Commons Recommended Citation Huberts, Dolores, "Whole Transcriptomic Expression Differences in EBV Immortalized versus Primary B- Cells" (2010). Undergraduate Honors Theses. Paper 347. https://scholarworks.wm.edu/honorstheses/347 This Honors Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. Whole Transcriptomic Expression Differences in EBV Immortalized versus Primary B-Cells A thesis submitted in partial fulfillment of the requirement for the degree of Bachelor of Science with Honors in Biology from the College of William and Mary in Virginia By Dolores Huberts Accepted for Honors ________________________________________ Lizabeth A. Allison, Director ________________________________________ Matthew Wawersik ________________________________________ Drew LaMar ________________________________________ Beverly Sher Williamsburg, Virginia December 17, 2010 ABSTRACT The Epstein–Barr Virus (EBV) is a human gamma herpes virus that infects more than 90% of the human population worldwide. It is commonly known in the US as the cause of Infectious Mononucleosis, and around the world as the cause of nasopharyngeal carcinoma and malignant lymphomas such as non-Hodgkin lymphoma, endemic Burkett’s lymphoma and Hodgkin lymphoma. Additionally, the EBV is used to immortalize cells to create cell lines for in-vitro studies. -
2020-Baroreflex-Dysfunction.Pdf
The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Baroreflex Dysfunction Horacio Kaufmann, M.D., Lucy Norcliffe‑Kaufmann, Ph.D., and Jose‑Alberto Palma, M.D., Ph.D. he autonomic nervous system innervates all body organs, in- From the Department of Neurology, Dys‑ cluding the cardiovascular system. Smooth muscle in arteries, arterioles, autonomia Center, New York University School of Medicine, New York. Address and veins and pericytes in capillaries receive autonomic innervation, which reprint requests to Dr. Kaufmann at the T Dysautonomia Center, NYU Langone modulates vascular smooth-muscle tone and vessel diameter. Afferent sensory neurons with receptors monitoring local changes in the chemical and mechanical Health, 530 First Ave., Suite 9Q, New York, NY 10016, or at horacio . kaufmann@ environment provide the information that allows the autonomic nervous system to nyulangone . org. regulate blood flow within every organ and redirect cardiac output to vascular N Engl J Med 2020;382:163-78. beds as needed. The autonomic nervous system provides moment-to-moment control DOI: 10.1056/NEJMra1509723 1 of blood pressure and heart rate through baroreflexes. These negative-feedback Copyright © 2020 Massachusetts Medical Society. neural loops regulate specific groups of both sympathetic neurons sending nerve impulses to the vasculature, the heart, and the kidney and parasympathetic neurons sending nerve impulses to the sinus node of the heart. We describe the main features of baroreflexes and the clinical phenotypes of baroreflex impairment. Baroreflexes Baroreflexes enable the circulatory system to adapt to varying conditions in daily life while maintaining blood pressure, heart rate, and blood volume within a narrow physiologic range.